CYP2D64 polymorphism: A new marker of response to hormonotherapy in male breast cancer?

Abstract Background Tamoxifen remains the standard hormonotherapy for Male breast cancer patients (MBC). Previous studies, in women, tried to evaluate the impact of CYP2D6 polymorphisms in tamoxifen efficacy with conflicting results. Herein we analyze the relation between CYP2D6*4 polymorphism and s...

Full description

Saved in:
Bibliographic Details
Published in:Breast (Edinburgh) 2015-08, Vol.24 (4), p.481-486
Main Authors: Abreu, M.H, Gomes, M, Menezes, F, Afonso, N, Abreu, P.H, Medeiros, R, Pereira, D, Lopes, C
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Hormonal - therapeutic use
Breast Neoplasms, Male - drug therapy
Breast Neoplasms, Male - genetics
Breast Neoplasms, Male - mortality
Breast Neoplasms, Male - pathology
Chemotherapy, Adjuvant
CYP2D64 polymorphism
Cytochrome P-450 CYP2D6 - genetics
Cytochrome P-450 CYP2D6 - metabolism
Disease-free survival
Genetic Markers
Genotype
Hematology, Oncology and Palliative Medicine
Humans
Male
Male breast cancer
Mastectomy
Middle Aged
Neoplasm Recurrence, Local - epidemiology
Neoplasm Recurrence, Local - genetics
Neoplasm Staging
Overall-survival
Pharmacogenetics
Polymorphism, Genetic
Survival Analysis
Tamoxifen
Tamoxifen - therapeutic use
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Tamoxifen remains the standard hormonotherapy for Male breast cancer patients (MBC). Previous studies, in women, tried to evaluate the impact of CYP2D6 polymorphisms in tamoxifen efficacy with conflicting results. Herein we analyze the relation between CYP2D6*4 polymorphism and survival in MBC patients. Patients and methods Fifty-three patients, proposed to tamoxifen in adjuvant setting, were enrolled. Clinical information was collected from records and histological revision with additional immunochemistry analysis was done to better characterize the tumors. Comprehensive CYP2D6*4 genotyping from blood or tumor tissue was performed and translated into two predicted metabolic activity groups. Results Patients included in the two CYP2D6*4 groups did not differ concerning to age, histological characteristics, and primary treatments performed. Median age at diagnosis was 63 years-old and patients were submitted at least to mastectomy and adjuvant hormonotherapy. Recurrence was observed in 7 patients (13.2%) and 13 patients (25.5%) died with a 5-year disease-free survival of 86.2%. The poorer metabolizer group had a high risk for recurrence ( p  = 0.034) and this outcome effect remains in different subgroups: in tumors larger than 2 cm ( p  
ISSN:0960-9776
1532-3080
DOI:10.1016/j.breast.2015.04.010